Impact of sodium-glucose cotransporter-2 inhibitors on kidney outcomes in type 2 diabetes: A tertiary center experience

• Egile Nagusiak: Mohammed H Tawhari (Egilea), Raed A Aldahash (Egilea), Faisal M Almutairi (Egilea), Mahdi S Albogami (Egilea), Ahmad E Rokon (Egilea), Faisal A Alsomali (Egilea), Khaled H Alanazi (Egilea), Abdulrahman A Alshehri (Egilea), Talal H Almutairi (Egilea), Abdulrahman D Alharbi (Egilea), Rayan M Alghamdi (Egilea), Ibrahim H Tawhari (Egilea), Salih A Bin Salih (Egilea)
• Formatua: Liburua
• Argitaratua: Wolters Kluwer Medknow Publications, 2023-01-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

BACKGROUND: Diabetic nephropathy (DN) is a complication of chronic hyperglycemia associated with diabetes mellitus (DM). Several studies have demonstrated the positive impact of sodium-glucose cotransporter-2 (SGLT2) inhibitors on kidney outcomes. The objective of the study was to evaluate the effec...